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Abstract 
Retinitis pigmentosa (RP) is a group of hereditary retinal diseases, characterised by photoreceptor cell 
loss. Despite a substantial understanding of the mechanisms leading to cell death, an effective 
therapeutic strategy is sought. Our laboratory has previously demonstrated the neuroprotective 
properties of Norgestrel, a progesterone analogue, in the degenerating retina, mediated in part by the 
neurotrophic factor basic fibroblast growth factor (bFGF). In other retinal studies, we have also 
presented a pro-survival role for reactive oxygen species (ROS), downstream of bFGF. Thus, we 
hypothesized that Norgestrel utilises bFGF-driven ROS production to promote photoreceptor survival. 
Using the 661W photoreceptor-like cell line, we now show that Norgestrel, working through 
progesterone receptor membrane complex 1 (PGRMC1); generates an early burst of pro-survival 
bFGF-induced ROS. Using the rd10 mouse model of RP, we confirm that Norgestrel induces a similar 
early pro-survival increase in retinal ROS. Norgestrel-driven protection in the rd10 retina was 
attenuated in the presence of antioxidants. This study therefore presents an essential role for ROS 
signalling in Norgestrel-mediated neuroprotection in vitro and demonstrates that Norgestrel employs a 
similar pro-survival mechanism in the degenerating retina. 
 
Introduction 
Reactive oxygen species (ROS) are constantly being generated under normal conditions in aerobic 
respiration and for many years, they were described simply as destructive by-products of the process 
(Chance, 1979; Rhee, 2006). ROS accumulation has been associated with neurodegenerative diseases 
such as Alzheimer’s and Parkinson’s disease through induction of cellular damage and mitochondrial 
dysfunction, worsening disease progression (Gandhi & Abramov, 2012; Kim et al., 2015). In retinitis 
pigmentosa (RP), a group of neurodegenerative diseases of the retina, apoptosis has also been related 
with a high production of ROS (Carmody & Cotter, 2000; Tao, 2016; Usui et al., 2009). In recent 
years, however, our understanding of these molecules has changed and they are no longer associated 
solely with damage. It has become increasingly clear that ROS signalling is also involved in pro-
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survival mechanisms. It is acknowledged that ROS function as intracellular signalling molecules, 
when present in moderate quantities (Remacle et al., 1995; Rhee, 2006; Trachootham et al., 2008). 
Acting as second messengers, ROS often act in a pro-survival capacity (Groeger et al., 2009b; 
Trachootham et al., 2008), with previous studies from our group highlighting a protective role for 
ROS in the retina (Bhatt et al., 2010; Farrell et al., 2011; Groeger et al., 2009a, 2012; Mackey et al., 
2008). This is of interest, for the retina has high oxygen consumption. In addition, given that the retina 
is constantly converting light into neural signals (Eshaq et al., 2014), ROS are consequently produced 
from endogenous sources (Bhatt et al., 2010; Kim et al., 2015; Nishimura & Hara, 2016).  
Cytokines and neurotrophic factors have shown promise as therapeutics for neurodegenerative 
disorders, due to their neuroprotective effects and their ability to delay degeneration in RP and a 
variety of other diseases (Kolomeyer & Zarbin, 2014). Several studies suggest that these molecules 
can modulate the production of ROS in different systems (Ilatovskaya et al., 2013; Kirkland et al., 
2007; Lo & Cruz, 1995), including various cell types of the retina (He et al., 2014; Zheng et al., 
2009). Indeed, we have shown that basic fibroblast growth factor (bFGF) is linked to ROS synthesis 
in the retina (Groeger et al., 2012; O’Driscoll et al., 2008). More recent studies from our group have 
presented the synthetic progesterone, Norgestrel, as a potential therapeutic for retinal degeneration 
(Byrne et al., 2016a, 2016b; Doonan et al., 2011; Roche et al., 2016, 2017; Roche & Wyse-Jackson et 
al., 2016, Wyse-Jackson & Cotter, 2016). Working primarily through activation of progesterone 
receptor membrane complex 1 (PGRMC1) (Wyse Jackson et al., 2016a, 2016b), we have shown 
Norgestrel’s protective effects are dependent on bFGF production.  
Therefore, in light of the above studies, we hypothesized that Norgestrel utilises bFGF-driven ROS 
production to promote photoreceptor survival. The current study was designed to examine the role of 
ROS in Norgestrel-mediated neuroprotection. 
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Materials and methods 
Drugs, reagents, primers and antibodies 
All reagents were purchased from Sigma-Aldrich (Dublin, Ireland) unless otherwise stated. 
 
Cell culture 
The 661W retinal cone photoreceptor-like cell line was generously provided by Dr Muayyad Al-
Ubaidi (University of Oklahoma, Norman, USA). Cells were routinely grown in Dulbecco’s modified 
Eagle’s medium (DMEM, D6429), supplemented with 10% foetal bovine serum (FBS, F7524) and 
1% penicillin/streptomycin (P0781). Cultures were maintained in a sterile humidified atmosphere at 
37°C and 5% CO2. 500,000 cells were seeded in a T75 cm2 flask (Starstedt AG & Co, Nümbrecht, 
Germany) and allowed to attach overnight. Cells were then washed three times with phosphate-
buffered saline (PBS, pH 7.4) prior to addition of 20 µM Norgestrel (N2260) or the equivalent 
dimethyl sulfoxide (DMSO, D2650) in complete (for untreated cells) or serum-free medium. In the 
case of antioxidant treatments, cells were pre-treated for 1 h with the superoxide scavenger Tiron (4,5-
Dihydroxy-1,3-benzenedisulfonic acid disodium salt, #172553) at a concentration 1mM or with 100 
µM N-acetyl-L-cysteine (NAC, A7250) which is known to act both as a direct and indirect ROS 
scavenger since it is a precursor of reduced glutathione (Taherian et al., 2014). In order to block 
PGRMC1, cells were pre-treated for 10 min with 1 µM AG-205 (A1487) previously optimized (Wyse 
Jackson et al., 2016b), before Norgestrel treatment. DMSO, which has been widely used and verified 
not to affect the viability of cells (Hebling et al., 2015) and H2O (for Tiron and NAC) were used as 
vehicle controls.  After incubation at indicated times, cells were washed in PBS and detached using 
Accutase solution (A6964). 
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Detection of ROS and flow cytometry 
Intracellular ROS
 
production was measured using 2′,7′-dichlorofluorescein diacetate (DCFH-DA, 
#35845), a general oxidative stress indicator. This compound is converted to DCF which is detectable 
at FL-1 (530 nm) with excitation at 488 nm by flow cytometry. 50 µM DCFDA was added to cells 
and incubated for 30 min at 37°C before analysis on a FACScan flow cytometer (Becton Dickinson, 
Oxford, UK) with ROS production indicated by an increase in fluorescence. All samples were gated 
using the healthy population of the untreated sample and 10,000 gated events per sample were 
collected in the experiments. Each experimental condition was performed in technical triplicates and 
all graphs represent data obtained from at least three independent experiments. CellQuest software 
(Becton Dickinson) was used for data analysis. 
 
MTS assay for cell viability 
A colorimetric tetrazolium (MTS) assay (G3580; Promega, Madison, WI, USA) was used to 
determine the number of viable cells. 2,000 cells per well were seeded in 96-well culture plates 
(Starstedt). At 24 h post seeding, cells were washed and treated for times indicated. 20 μl of MTS 
solution was added to each well and incubated at 37°C in dark for the same time as treatment, leaving 
it for a maximum of 4 h in the case of 6 h treatment. The quantity of formazan product as measured 
by absorbance at 490 nm with a Spectramax Plus 384 microplate reader (Molecular Device 
Corporation, Sunnyvale, CA, USA) is directly proportional to the number of living cells in culture. A 
further reading at 650 nm was also taken from all wells and deducted from the 490 nm readings to 
account for any cellular debris. Untreated healthy cells were used as control and all treatments were 
compared to 100% viable control. All samples were carried out in 6 replicates in a total of at least 
three independent experiments. 
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Small interfering RNA (siRNA) silencing 
661W cells (300,000) were seeded in a T75 flask the day before transfection. Both 25 nM FGF2 
siRNA (GS14173, Qiagen) and AllStars Negative Control siRNA (Qiagen) were transfected and 
incubated for 48 h using HiPerFect Transfection Reagent (Qiagen). Mock transfected cells and cells 
treated with HiPerFect Transfection Reagent alone were included as a siRNA negative control. Cells 
were then washed three times in PBS followed by treatment with 20 µM Norgestrel or DMSO 
(vehicle) in serum-free medium. siRNA knockdown was validated by RT-qPCR and 
immunofluorescence. 
 
RNA isolation, cDNA synthesis and quantitative real time PCR (RT-qPCR) 
Total RNA isolation from 661W cells was performed using an RNeasy Mini Kit (Qiagen, West 
Sussex, UK) following manufacturer’s protocol, including DNase treatment. 1 µg of cDNA was 
synthesized using QuantiTect Reverse Transcription Kit (Qiagen) to perform RT-qPCR with 
QuantiTect Primer Assays (β-Actin, QT00095242; Gapdh, QT00199388; Hprt, QT00166768; Fgf2, 
QT00128135) and QuantiTect SYBR Green PCR Kit (Qiagen) in 96 well-plates (Roche, West Sussex, 
UK). Samples were run in triplicates using LightCycler®96 Instrument (Roche) whose protocol 
include: denaturing at 95°C for 10 min, followed by 40 cycles of 10 s at 95°C, 10 s at 60°C for and 10 
s at 72°C. mRNA values (Ct) were obtained using LightCycler®96 Application Software (Roche) and 
normalized to the average of three housekeeping genes (β-Actin, Gapdh and Hprt). Relative changes 
in gene expression were quantified using the comparative Ct (ΔΔCt) method (Livak & Schmittgen, 
2001). 
 
Immunofluorescence 
25,000 cells were seeded on glass coverslips overnight in 24 well plates (Starstedt) prior treatment. 
Cell were then washed in PBS and fixed with 4% paraformaldehyde (PFA) for 20 min at room 
temperature (RT), followed by blocking for 30 min at RT with 5% donkey serum (containing 0.1% 
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Triton X-100 for permeabilization). Coverslips were subsequently incubated with purified mouse anti-
bFGF antibody (#610073; BD Biosciences Europe, Oxford, UK) at a dilution 1:250 in 5% donkey 
serum overnight at 4°C. After washes, conjugated secondary antibody (1:5000; Alexa Fluor 488 
donkey anti-mouse, Life Technologies, Eugene, OR, USA) was used for 1.5 h in dark at RT. All 
coverslips were incubated with Hoechst 33342 (1 μg/ml) for 10 min at RT in dark to counterstain the 
nuclei. Coverslips were mounted on to glass slides using Mowiol and imaged using a fluorescent 
microscope Leica DM LB2 (Leica Co., Wetzlar, Germany). 
Mice 
All animals were handled and maintained following the Association for Research in Vision and 
Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research (License 
Number AE19130/P009). Experiments were approved by University College Cork Animal 
Experimentation Ethics Committee. Both male and female homozygous rd10/rd10 mice (B6.CXBI-
Pde6brd10/J) and C57BL/6 mice (C57) were used as controls. Mice were supplied by the Biological 
Services Unit, University College Cork and were humanely euthanized by cervical dislocation. 
 
FACS analysis in retinal explants 
Eyes were removed and retinas explanted as previously described (Wyse Jackson et al., 2016a), using 
a total number of 4 mice per treatment. Retinal explants were treated with 20 µM Norgestrel or the 
equivalent DMSO (vehicle) at the time points indicated. In the case of treatment with an antioxidant, 
cells were treated with 1mM Tiron or H2O (vehicle) for 1 h. Explants were then transferred to a 
trypsin-EDTA solution 0.25% (T4049) containing 50 μL deoxyribonuclease II from bovine spleen 
(10,000 units/ml; D8764) and maintained at 37°C for 15 min. Single-cell suspensions were made by 
pipetting up and down ten times using a P1000 pipette and large debris was allowed to settle. Then, 4 
ml of single-cell suspension were collected and placed into a FACS tube (BD Biosciences) and 
incubated with 50 µM DCFDA for 15 min at 37°C. Fluorescence was measured using a Becton-
Dickinson FACScan flow cytometer.  
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TUNEL staining 
Localization of dying cells within retinal explants was assessed with the terminal dUTP nick end-
labelling (TUNEL) assay on fixed tissue as previously described (Roche et al., 2016). Frozen retinal 
sections were permeabilized with 0.1% Triton X for 2 min followed by incubation with terminal 
deoxynucleotidyl transferase (M1875; Promega, Wisconsin, US) and fluorescein-12-dUTP 
(#11373242910; Roche, Lewes, UK) according to manufacturer’s instructions. Nuclei were 
counterstained with Hoechst 33342 (1 μg/mL). Sections were incubated at 37°C for 1 h in a 
humidified chamber. After three washes with PBS, sections were mounted in Mowiol and viewed 
under a fluorescence microscope (LeicaDMLB2). For each treatment, at least three animals were used 
and two fields (x40 magnification) per section of at least three different sections were evaluated. 
Quantification was performed using ImageJ software. Per section, three distinct measurements were 
taken and averaged from at least four sections per mouse. 
 
Statistical analysis 
Numerical data were compiled using Microsoft Excel (Microsoft, Dublin, Ireland) and expressed as 
mean ± standard error (SEM) from at least three separate experiments, with each being performed in 
triplicate. In the case of two sample comparisons (vehicle vs. Norgestrel), significant differences 
across groups were assessed with an unpaired Student’s t-test using the GraphPad Prism 6 software. 
One-way ANOVA and post hoc Tukey’s test were used for multiple comparisons and post hoc 
Dunnett’s test was used when groups were only compared with one control group (untreated, 
Scrambled). Differences were considered significant if P < 0.05 indicated on the graphs with asterisks 
(*). 
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Results 
Serum deprivation induces a pro-survival production of ROS in 661W cells 
To confirm that serum starvation produces ROS as previously reported (Mackey et al., 2008), cells 
were incubated with 2’,7’-dichlorofluorescin diacetate (DCFDA), one of the most commonly used 
probes for detecting intracellular ROS levels (Eruslanov & Kusmartsev, 2010; Karlsson et al., 2010). 
Untreated 661W cells (UT) were used to gate the population analysed in all subsequent experiments 
(Fig. 1A). A significant increase in ROS was observed at 30 min and up to 1 h in serum-starved cells 
compared to vehicle control (one-way ANOVA, serum starvation effect, F 4,39 = 66.91, P < 0.0001; 
Dunnett’s post hoc test, 30 min: P < 0.0001; 1 h: P = 0.003; n = 3 per group; Fig. 1B). 
 
To establish whether this burst of ROS is beneficial to 661W cells, the antioxidants sodium 4,5-
dihydroxybenzene-1,3-disulfonate (Tiron) or N-acetyl-L-cysteine (NAC) were used to inhibit the 
increase in ROS (Taherian et al., 2014) (independent samples t-test, Tiron: t
 16 = 7.313, P < 0.0001; 
NAC: t 16 = 2.324, P = 0.0336, n = 3 per group; Fig. 1C(i)). Cells pre-treated with vehicle and 
maintained in serum-free media for 30 min displayed a decrease in cellular viability compared to 
untreated cells (one-way ANOVA, serum starvation effect, F 3,88 = 30.63, P = 0.0008; Tukey’s HDS 
post hoc test, P < 0.0001; n = 4 per group; Fig. 1C(ii)). Pre-treatment with Tiron or NAC resulted in a 
further decrease in cell viability (Tukey’s HDS post hoc test, Tiron: P < 0.0001; NAC: P < 0.0001). 
These data suggest that the presence of ROS is essential for cells to survive normally, given that cells 
treated with Tiron or NAC showed even more cell death than cells treated with vehicle control only 
(Tukey’s HDS post hoc test, Tiron: P = 0.004; NAC: P = 0.0411). 
 
Norgestrel induces a pro-survival production of ROS in serum-deprived 661W cells 
Previous studies from this group have documented the protective effects of Norgestrel in the stressed 
661W photoreceptor-like cell line (Doonan et al., 2011; Wyse Jackson & Cotter, 2016). Here, we 
sought to understand the role that ROS play in the Norgestrel-mediated response. By means of flow 
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cytometry analyses, Norgestrel significantly increased ROS levels at 30 min following serum-
starvation compared to vehicle control (independent samples t-test, t 18 = 3.277, P = 0.0042; n = 3-4 
per group; Fig. 2A). The use of DMSO as vehicle also increases ROS levels in all time points 
compared with the UT cells (Fig. 2A), possibly through its anti-inflammatory effects. For this reason, 
these serum starved samples are not comparable with samples in Fig. 1B. MTS assay was used to 
analyse cellular viability and proliferation with Norgestrel over time. Norgestrel enhanced cell 
survival at all time points studied (independent samples t-test, 30 min: t 34 = 3.503, P = 0.0015; 1 h: t 
34 = 3.805, P = 0.0006; 3 h: t 34
 
= 4.182, P = 0.0002; 6 h: t 34 = 2.644, P = 0.0105; n = 3-4 per group; 
Fig. 2B), suggesting that ROS production is linked to an increase in cell survival. In order to test this 
hypothesis, the antioxidants Tiron and NAC were again used to block the increase in ROS 1 h prior to 
Norgestrel treatment. Cells pre-treated with vehicle (H2O) were protected by Norgestrel following 30 
min of serum deprivation (independent samples t-test, t 33 = 3.002, P = 0.0051; n = 3 per group; Fig. 
2C). However, Norgestrel was no longer protective in the presence of the antioxidants compared with 
the vehicle only (Tiron: t 40 = 3.916, P = 0.0003; NAC: t 41 = 6.204, P < 0.0001; n = 4 per group). 
Thus, the protective effects of Norgestrel in serum-deprived 661W cells are dependent on ROS 
production. 
 
Norgestrel accelerates the early survival response in stressed 661W cells 
The early ROS-mediated response which takes place in the first minutes after serum deprivation has 
been documented to induce cell survival (Groeger et al., 2009a; Mackey et al., 2008). To examine the 
effects of Norgestrel on this early pro-survival burst of ROS, cells were serum-starved and treated 
with either Norgestrel or vehicle (DMSO) for shorter time points of 1-20 min. Norgestrel treatment 
increased ROS levels from 5 min (independent samples t-test, t 16 = 7.748, P < 0.0001; n = 3 per 
group; Fig. 3A) compared to serum starved control (vehicle). The study of the whole response over 
time showed that increased levels of ROS were maintained up to 30 min following Norgestrel 
treatment (10 min: t 16 = 2.172, P = 0.0463; 20 min: t 16 = 3.665, P = 0.0021; 30 min: t 18 = 3.277, P = 
0.0042; n = 3 per group; Fig. 3B) but no difference in response was detected beyond this point. These 
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data show that Norgestrel enhances the early pro-survival response of increased ROS levels in serum-
starved 661W cells. 
 
Norgestrel signals through progesterone receptor membrane component 1 (PGRMC1) to 
mediate redox signalling 
Previous studies have shown that PGRMC1, a membrane-localised progesterone receptor, is 
responsible for the neuroprotective actions of Norgestrel (Wyse Jackson et al., 2016a, 2016b). 
Therefore, FACS analysis was performed in order to investigate its role in ROS production. The 
specific inhibitor AG-205 was used to block PGRMC1 in stressed 661W cells in a concentration that 
does not affect cellular viability (Wyse Jackson et al., 2016b). The burst of ROS produced by 
Norgestrel (independent samples t-test, t 16 = 4.096, P = 0.0008; n = 3 per group; Fig. 4) was 
abrogated when PGRMC1 was inhibited as detected by decreased DCFDA fluorescence intensity (t 16 
= 6.185, P < 0.0001; n = 3 per group), suggesting the importance of the receptor in this response. 
 
Inhibition of bFGF abrogates the Norgestrel-induced increase in ROS in serum-starved 661W 
cells 
We have previously shown that Norgestrel elicits its neuroprotective effects in 661W cells at least in 
part by up-regulating the growth factor, basic fibroblast growth factor (bFGF) (Doonan et al., 2011; 
Wyse Jackson & Cotter, 2016). In other studies, addition of bFGF led to increased ROS production in 
the photoreceptors of retinal explants (Farrell et al., 2011). We therefore sought to establish if 
Norgestrel-induced increases in ROS were dependent on bFGF activity. Firstly, we show serum-
starvation alone in 661W cells does not up-regulate bFGF expression (one-way ANOVA, serum 
starvation effect, F 4,51 = 1.924, P = 0.1206; n = 3-4 per group; Fig. 5A(i)). However, when treated 
with Norgestrel, 661W cells displayed increased expression of bFGF following 30 min of serum-
starvation (independent samples t-test, t 21 = 2.844, P = 0.0097; n = 4 per group; Fig. 5A(ii)). To 
understand whether bFGF is involved in the redox response produced by Norgestrel at 30 min, siRNA 
was used to knockdown bFGF over 48 h. A significant reduction in bFGF expression was verified 
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through RT-qPCR (one-way ANOVA, time of incubation siRNA, F 2,15 = 65.95, P < 0.0001; 
Dunnett’s post hoc test, 24 h: P = 0.0002; 48 h: P < 0.0001; n = 2 per group; Fig. 5B(i)) and by 
immunofluorescence (Fig. 5B(ii)). siRNA-treated cells were then serum-starved and treated with 
either DMSO (vehicle) or 20 µM Norgestrel for 30 min before ROS were measured using DCFDA. 
Norgestrel was unable to increase ROS when bFGF was knocked down, suggesting that this response 
is bFGF-dependent (independent samples t-test, t 37 = 2.198, P = 0.0343; n = 5 per group; Fig. 5C). 
 
Norgestrel induces an increase in ROS production in photoreceptors ex vivo 
Results from this study thus far demonstrate that Norgestrel, through bFGF, utilises ROS signalling to 
promote neuronal survival of the 661W cell line. Therefore, we next sought to evaluate the 
contribution of ROS to Norgestrel-mediated protection of photoreceptors in the retina. Using retinas 
from the rd10 model of retinitis pigmentosa (Roche et al., 2016) we prepared single-cell suspensions 
as previously described, to be used for FACS analysis (Byrne et al., 2016b). In order to confirm the 
photoreceptor population, we compared a P30 C57 wild-type retinal preparation to that of a P30 rd10. 
The rd10 retina has undergone extensive photoreceptor loss by P30 (Roche et al., 2016). Thus, since 
the C57 wild-type retina presented a population of cells that were absent from the rd10 retina (Fig. 
6A), we understood this population to represent photoreceptors. This method of gating rd10 
photoreceptors has previously been published (Byrne et al., 2016b). We subsequently evaluated the 
effects of Norgestrel on single cell suspensions from P15 rd10 retinas, a suitable timepoint as 
photoreceptors have initiated cell death mechanisms but photoreceptor loss is not yet apparent (Roche 
et al., 2016; Roche & Wyse-Jackson et al., 2016). Retinal cell suspensions were treated with either 20 
µm Norgestrel or DMSO (vehicle) over 3 hours and analysed for changes in photoreceptor ROS 
production. The population of photoreceptors from rd10 retinas treated with Norgestrel showed an 
increase in ROS production compared to those treated with vehicle control, at 30 min and 1 h 
(independent samples t-test, 30 min: t 22 = 2.486, P = 0.021; 1 h: t 22 = 3.723, P = 0.0013; n = 4 per 
group; Fig. 6B). Interestingly, Norgestrel-mediated reduction in photoreceptor cell death was only 
evident at 1 h, as assessed by the TUNEL assay (independent samples t-test, independent samples t-
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
test, 30 min: t 20 = 0.1706, P = 0.8663; 1 h: t 18 = 3.211, P = 0.0068; n = 3 per group; Fig. 6C). 
Therefore, we observed an increase in ROS prior to the Norgestrel-mediated protection of 
photoreceptors.  
In order to determine if this increase in photoreceptor ROS is necessary for Norgestrel-mediated 
protection in rd10 explants, we utilised the antioxidant Tiron. C57 explants pre-treated with 1mM 
Tiron showed a significant decrease in their basal levels of ROS compared to H2O vehicle control, as 
indicated by flow cytometry. This suggests that 1 mM Tiron is a suitable method by which to abrogate 
ROS production in retinal explants (independent samples t-test t 16 = 3.337, P = 0.0042; n = 3 per 
group; Fig. 6D(i)). P15 rd10 explants were consequently pre-treated for 1 h with 1 mM Tiron before 1 
h treatment with Norgestrel or DMSO (vehicle). TUNEL assay revealed that Norgestrel could no 
longer protect rd10 explants from photoreceptor cell death over 1 h, when ROS production was 
inhibited through Tiron antioxidant (independent samples t-test t 29 = 0.06121, P = 0.9516; n = 4 per 
group; Fig. 6D(ii)). This supports our findings in 661Ws that Norgestrel initiates a pro-survival burst 
of ROS, assisting in the survival of retinal photoreceptor cells.  
 
Discussion 
Studies investigating the role of ROS in cell survival have uncovered contrasting findings (Rhee, 
2006). In the retina, we have previously documented both protective and detrimental properties of 
ROS signalling (Groeger et al., 2009b; Byrne et al., 2016b). Under normal conditions, cells maintain 
a delicate balance between ROS production and elimination through many mechanisms. Thus, any 
alteration that disrupts this redox homeostasis can cause an increase of intracellular ROS and thus, 
oxidative stress. In this way, ROS become cytotoxic under specific conditions. For instance if an 
increased production occurs at the wrong time or place, if the signal is too strong or if it persists for 
long periods of time (Nathan & Cunningham-Bussel, 2013; Trachootham et al., 2008). Several 
therapeutic strategies of the retina have utilised this system: increasing antioxidant machinery in order 
to reduce oxidative stress and increase survival (Komeima et al., 2006; Taherian et al., 2014). Indeed, 
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studies from our group demonstrate that Norgestrel can reduce the damaging ROS produced after 24-
48 h light exposure. This enhances neuroprotection in the balb/c light damage mouse model of retinal 
degeneration, and involves the up-regulation of the antioxidant transcription factor Nrf2 (Byrne et al., 
2016).  
 
Nevertheless, to state that these molecules are always damaging would be an oversimplification, for 
ROS can have opposing effect since under different physiological conditions. In fact, under normal 
physiological conditions, moderate levels of ROS participate in many biological processes as second 
messengers or intermediates (Holmström & Finkel, 2014; Remacle et al., 1995; Rhee, 2006). For this 
reason, the implication of ROS in survival responses has gained attention. Previous studies from our 
lab have shown that hydrogen peroxide (H2O2) acts as a second messenger in intracellular signalling 
pathways inducing cell survival in 661W cells and C57BL/6 retinal explants (Groeger et al., 2009a; 
2009b; Mackey et al., 2008). The current study also reveals how these molecules have a survival 
nature in the first 30 min of 661W serum deprivation (Fig. 1). In light of previous and current 
findings, it therefore appears that ROS signalling can play a protective or detrimental role depending 
on the intensity, cellular location and period of the event. 
Norgestrel-mediated neuroprotection has been demonstrated in different neuronal/retinal degeneration 
models (Byrne et al., 2016; Roche et al., 2016; Wyse Jackson & Cotter, 2016). The importance of the 
current study was to understand the role that ROS play in this response. Norgestrel, acting through the 
progesterone receptor PGRMC1 (Fig. 4) (Wyse Jackson et al., 2016a), increases bFGF expression 
(Fig. 5) (Wyse Jackson & Cotter, 2016) resulting in an early up-regulation of ROS levels in 661W 
cells (Fig. 2 and 3). Decreasing ROS production using two different antioxidants (Tiron and NAC) 
revealed the survival nature of these molecules (Fig. 1 and 2). Future studies will investigate the 
downstream pathways stimulated by ROS upregulation, leading to enhanced survival.  
Results from the 661W photoreceptor-like cell line (Fig. 1-5) suggested that Norgestrel’s 
neuroprotective role in the retina involved an up-regulation of pro-survival ROS. In order to 
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substantiate this claim, we next employed the rd10 mouse model of retinitis pigmentosa. Using single 
cell suspensions of retinal explants for FACS analysis, we investigated the response of photoreceptors 
to Norgestrel, in terms of ROS levels. Given that the aim of the study was to analyse the response in 
the photoreceptor layer, we harvested retinas at postnatal day (P) 15, prior to the loss of 
photoreceptors which takes place from P18~P21 in the rd10 retina (Barhoum et al., 2008; Roche et 
al., 2016). Norgestrel produced a similar early increase in ROS levels from 30 min in photoreceptors 
of the rd10 retina (Fig. 6). We hypothesize that this peak in the production of ROS might be in some 
part responsible for the proceeding decrease in TUNEL-positive staining observed at 1 h following 
Norgestrel treatment, in light of our findings in 661W cells and rd10 explants pre-treated with 
antioxidants (Fig. 6). In support of this, ROS have been implicated in survival mechanisms in the 
retina (Groeger et al., 2009a, 2012) and in other systems (Mackenzie et al., 2013; Shafique et al., 
2013; Trachootham et al., 2008).  
In summary, this study presents an important aspect to Norgestrel’s neuroprotective properties, up-
regulating ROS production as an immediate response, through the activation of PGRMC1 and 
increased production of bFGF (Fig. 7). This early burst of ROS is an essential step, as Norgestrel’s 
neuroprotective effects are prevented in the presence of antioxidants. Although this early burst of 
ROS is short-lived, the protective effects of Norgestrel persist for several weeks in a mouse model of 
RP (Roche & Wyse-Jackson et al., 2016), with Norgestrel affecting various cellular and molecular 
targets throughout the course of degeneration (Byrne et al., 2016a, 2016b; Roche et al., 2016, 2017; 
Roche & Wyse Jackson et al., 2016; Wyse Jackson & Cotter, 2016). The current study therefore 
reinforces the prospect of Norgestrel as a therapeutic for retinal degeneration, utilising ROS signalling 
in the early stages of injury to promote survival. 
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Figure Legends 
Figure 1. Serum deprivation induces a pro-survival production of ROS in 661W cells. (A) A 
healthy population of untreated (UT) cells was gated for all samples. (B) DCFDA probe was used to 
detect ROS levels by flow cytometry and plotted on a histogram. Y-axis represents cell counts, x-axis 
(logarithmic scale) measures the level of fluorescence. A shift to the right along the x-axis represents 
an increase in DCFDA fluorescence and hence ROS levels. Geomeans were graphed compared to UT 
cells (Dunnett’s post hoc test, comparing all time points to the UT control). Cells following serum 
starvation (SS) increased ROS levels at 30 min and up to 1 h. (C) (i) Antioxidants Tiron and NAC 
decreased the ROS production in 661W cells (t-test comparing individual treatments to their vehicle 
control). (ii) Changes in cell viability were measured by the MTS assay and graphed as a percentage 
of 100% viable UT control (Tukey’s HDS post hoc test for multiple comparisons). SS decreased cell 
viability at 30 min. Stressed cells pre-treated with antioxidants showed a further decrease in survival 
compared with the vehicle. Asterisks indicate significant difference (* P < 0.05, ** P < 0.01, *** P < 
0.001, **** P < 0.0001). 
 
Figure 2. Norgestrel induces a pro-survival production of ROS in serum-deprived 661W cells. 
(A) FACS analysis of 661W cells treated with 20 µM Norgestrel or vehicle control (DMSO) 
following SS. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of 
fluorescence. A shift to the right along the x-axis represents an increase in DCFDA fluorescence and 
hence ROS levels. Geomeans were graphed compared to UT cells (t-test comparing individual 
Norgestrel treatments to their timed vehicle control). ROS production was increased by Norgestrel at 
30 min. (B) MTS assay showed Norgestrel enhanced cell survival in all time points studied compared 
with the vehicle control (t-test comparing individual Norgestrel treatments to their timed vehicle 
control). (C) Antioxidants were used to reduce ROS production following serum starvation. 
Norgestrel was able to rescue cells pre-treated with the vehicle (H2O), whereas Norgestrel was no 
longer protective in the presence of antioxidans. Asterisks indicate significant difference (* P < 0.05, 
** P < 0.01, *** P < 0.001, **** P < 0.0001). 
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Figure 3. Norgestrel accelerates the early survival response in stressed 661W cells. (A) Various 
time points up to 30 min were analysed following Norgestrel treatment by flow cytometry and plotted 
on a histogram. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of 
fluorescence. A shift to the right along the x-axis represents an increase in DCFDA fluorescence and 
hence ROS levels. Geomeans were graphed compared to UT cells (t-test comparing individual 
Norgestrel treatments to their timed vehicle control). Norgestrel induced a significantly higher 
response compared with vehicle from 5 min. (B) Timeline of ROS levels in response to Norgestrel in 
stressed 661W cells. Norgestrel stimulated increased ROS production from 5 min and up to 30 min 
when levels reverted to normal. Asterisks indicate significant difference (* P < 0.05, ** P < 0.01, 
**** P < 0.0001). 
 
Figure 4. Norgestrel signals through progesterone receptor membrane component 1 (PGRMC1) 
to mediate redox signalling. 661W cells were treated with the PGRMC1 specific inhibitor AG-205 
prior to serum starvation for 30 min and Norgestrel treatment. DMSO was used as vehicle control. 
DCFDA probe was used to detect ROS levels by flow cytometry and plotted on a histogram. Y-axis 
represents cell counts, x-axis (logarithmic scale) measures the level of fluorescence. A shift to the 
right along the x-axis represents an increase in DCFDA fluorescence and hence ROS levels. 
Geomeans were graphed compared to UT cells (t-test comparing individual treatments). PGRMC1 
inhibition abrogated the burst of ROS produced by Norgestrel. Asterisks indicate significant 
difference (NS not significant, **** P < 0.0001). 
 
Figure 5. Inhibition of bFGF abrogates Norgestrel-induced increases in ROS in serum-starved 
661W cells. (A) bFGF mRNA levels were measured in 661W following SS ((i), Dunnett’s post hoc 
test, comparing all time points to the UT control)  and treated with Norgestrel over time by RT-PCR 
((ii), t-test comparing individual Norgestrel treatments to their timed vehicle control). bFGF up-
regulation only took place in the presence of Norgestrel. (B) bFGF levels detected by RT-PCR (i) and 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
immunofluorescence (ii) in 661W cells transfected with siRNA targeted against bFGF. Scale bar 30 
µm. (C) FACS analysis of cells transfected with bFGF siRNA treated with DMSO or Norgestrel. Y-
axis represents cell counts, x-axis (logarithmic scale) measures the level of fluorescence. A shift to the 
right along the x-axis represents an increase in DCFDA fluorescence and hence ROS levels. 
Geomeans were graphed compared to UT cells (t-test comparing individual treatments). bFGF 
knockdown prevented the increase of ROS produced by Norgestrel (scrambled vs siRNA). Asterisks 
indicate significant difference (NS not significant, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 
0.0001). 
Figure 6. Norgestrel induces an increase in ROS production in photoreceptors ex vivo. (A) 
Photoreceptor population was gated using P30 C57BL/6 wild type and rd10 retinas, as this population 
was absent from rd10 retinas. (B) FACS analysis of photoreceptors using single cell suspensions from 
P15 rd10 retinas. Y-axis represents cell counts, x-axis (logarithmic scale) measures the level of 
fluorescence. A shift to the right along the x-axis represents an increase in DCFDA fluorescence and 
hence ROS levels. Geomeans were graphed and individual Norgestrel treatments were compared to 
their timed DMSO vehicle control (t-test). Norgestrel up-regulated ROS levels at 30 min and up to 1 
h. (C) Apoptosis of retinal cells in the outer nuclear layer (ONL) was detected by TUNEL (green) at 
30 min (i) and at 1 h (ii). Norgestrel reduced TUNEL-positive staining in the central rd10 retina after 
1 h treatment, but not at 30 min compared with the vehicle control. (D) (i) FACS analysis of 
photoreceptors from C57BL/6 retinas. Treatment with antioxidant Tiron for 1 h reduced significantly 
ROS levels. (ii) TUNEL assay in ONL of P15 rd10 retinas. Norgestrel was not able to reduce 
TUNEL-positive staining after 1 h treatment in the presence of Tiron. Scale bar 50 µm. Asterisks 
indicate significant difference (NS not significant, * P < 0.05, ** P < 0.01).  
 
Figure 7. Schematic representation of Norgestrel-mediated pro-survival redox signalling. This 
shows the proposed pathway Norgestrel uses to promote neuroprotection in serum-starved 661W 
cells, including the compounds used to inhibit each step. 
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